 Bloomberg |
Amylin Pharma rises on report of new sale talks
CBS News THE BIG PICTURE: Amylin sells the diabetes treatments Bydureon and Byetta. The company reportedly rejected a buyout offer from Bristol-Myers Squibb Co. earlier this year, and it is being sued by billionaire investor Carl Icahn. Amylin Said to Seek Buyers After Rejecting Bristol-MyersBloomberg Exclusive: Amylin explores sale, hires bankers: sourcesReuters Amylin Is Said to Pursue a SaleNew York Times all 51 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.